Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
How will COVID-19 impact value-based models?
COVID-19 has left providers with fewer in-office visits, more telehealth appointments and, for many, reduced revenue.
But even as doctors struggle with the day-to-day challenges of practicing under radically new circumstances, some health care policy makers, academics and payers are asking another question: What do the changes caused by the pandemic mean for accountable care organizations (ACOs) and other value-based care models, under which doctors and practices are rewarded for keeping patients healthy while holding costs down?
Read from experts who spoke to our sister publication, Medical Economics on this topic.
Related Videos
Related Content
